COVID-19 drug reaches Odisha

Bhubaneswar: Hyderabad-based Hetero Healthcare Ltd’s Covifor, the generic version of COVID-19 drug Remdesivir, reached Odisha, an official of the Health Department said today.

The drug will be used for critical COVID-19 patients undergoing treatment at COVID hospitals in the state, the official added.

The drug is available in 100 mg vials (injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner, the company said in a statement.

The maximum retail price has been fixed at Rs 5,400 per vial for the drug.

Pharma major Cipla has also said it will price its generic version of Remdesivir at less than Rs 5,000 per vial.

On the other hand, the state will receive its first consignment of COVID-19 drug FabiFlu (favipiravir) manufactured by Glenmark Pharmaceuticals Limited. Around 1200 strips of the drug will be sent to different hospitals in the state for treatment of COVID patients.

For 36 years, Sambad Group has been redefining Odia journalism and bringing you the news from all corners of the state and beyond. During this pandemic, support Sambad and Kanak News by making a contribution today for our various digital platforms. Help regional journalism survive during these challenging times.

Also Read

Leave A Reply

Your email address will not be published.